Indian generics escalate pressure on Novo Nordisk's weight-loss drug patent
Novo Nordisk's patent battle in India has intensified following coordinated legal challenge against the Danish pharmaceutical giant's blockbuster weight-loss drug, semaglutide, sold under the brand names Wegovy and Ozempic. Six new patent-infringement...To view the full article, register now.
Already a subscriber? Click here to view full article